Trial Profile
Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma an Open-label,Phase 1 Study.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 10 May 2023
Price :
$35
*
At a glance
- Drugs Donafenib (Primary)
- Indications Carcinoma; Nasopharyngeal cancer
- Focus Adverse reactions
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 04 May 2023 Status changed from recruiting to discontinued. (Corporate policy adjustments)
- 15 Oct 2020 Planned End Date changed from 1 Sep 2020 to 1 Sep 2023.
- 15 Oct 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2023.